All Oncology articles – Page 6
-
NewsKidney tumour organoids offer new drug testing platform
Scientists in China have used 3D bioprinting to grow kidney tumours from patients’ own cells, creating realistic models that could speed up development of personalised treatments.
-
ReportBeyond the Lab: Biomarkers Powering Tomorrow’s Therapies
Biomarkers are redefining how precision therapies are discovered, validated and delivered. This exclusive expert-led report reveals how leading teams are using biomarker science to drive faster insights, cleaner data and more targeted treatments – from discovery to diagnostics.
-
NewsCOVID-19 and flu could awaken hidden breast cancer cells
Scientists have discovered that infections like COVID-19 and flu can “wake up” dormant breast cancer cells – triggering new tumour growth in the lungs.
-
NewsNew research shows squeezing cancer cells helps them survive
Scientists have discovered that cancer cells generate an instant burst of energy when physically squeezed, helping them repair DNA damage and survive harsh environments. This discovery means that therapies targeting this new survival mechanism could be developed.
-
NewsNew drug combo targets PRMT5 to fight deadly cancers
Scientists at Virginia Tech’s Fralin Biomedical Research Institute have identified a promising drug target – PRMT5 – that could make treatment-resistant lung, brain and pancreatic cancers more vulnerable to therapy.
-
ArticleFrom lab to clinic: the rise of Radio-DARPins in oncology
As radioligand therapy continues to show promise, its application in solid tumours remains limited by long-standing biological challenges. In this interview, Julien Torgue, CSO at Orano Med, discusses a new collaborative platform – Radio-DARPins – and how it could help overcome key barriers to clinical progress.
-
NewsDeep-sea sugar EPS3.9 sparks immune attack on tumours
Scientists have isolated a sugar molecule from deep-sea bacteria that triggers pyroptosis - a form of inflammatory cell death - to halt tumour growth - highlighting the potential of marine microbes in drug development.
-
NewsNew sticky material mimics gecko feet to fight tumours
Inspired by the gecko lizard’s grip, scientists at CU Boulder have developed a sticky, biodegradable material that clings to tumours and delivers chemotherapy drugs over several days.
-
NewsNew AI model PROTsi identifies aggressive tumours using protein markers
Researchers in Brazil and Poland have developed an AI-powered tool that predicts cancer aggressiveness by analysing protein expression - offering new insights into tumour behaviour.
-
NewsTargeting MAPK and PI3K/mTOR pathways halts ovarian cancer growth
A new preclinical study has combined two experimental drugs that effectively block ovarian tumour growth – a strategy that could lead to new treatments against this genetically complex cancer.
-
ArticleNGS is evolving: collaboration and tech lead the way
Next-generation sequencing (NGS) is advancing fast – and it’s not happening in isolation. Strategic partnerships and automation are streamlining workflows and reshaping what's possible in genomics research.
-
NewsMitochondria: melanoma’s hidden vulnerability
Scientists at Lund University have shown that aggressive melanoma tumours are driven by overactive mitochondrial processes – revealing a potential treatment strategy using drugs already approved for other conditions.
-
News
Gene therapy boosts CAR-T power against glioblastoma
Researchers at SR-TIGET in Milan have developed a novel gene therapy approach that supercharges CAR-T cell therapy against glioblastoma – strengthening treatment against one of the world’s deadliest brain cancers.
-
NewsLINC01235 identified as driver of aggressive breast cancer
Researchers at Cold Spring Harbor Laboratory have demonstrated that an obscure RNA molecule, LINC01235, plays a crucial role in the progression of aggressive triple-negative breast cancer (TNBC) – potentially allowing for the development of targeted therapies against it.
-
ArticleHow dual-targeting ADCs aim to tackle resistance
Find out how dual-target ADCs and tumour-specific Treg depletion are shaping the next wave of targeted cancer therapies.
-
NewsDisabling the SETD1B enzyme halts leukaemia cell growth
Japanese researchers have identified the epigenetic enzyme SETD1B as a key driver of aggressive acute myeloid leukaemia (AML) – which could lead to new treatment strategies targeting the cancer’s underlying biology in the future.
-
ArticleThe AI model that is changing clinical trial design
AI is changing how clinical trials are run - quietly but significantly. Find out how digital twins are helping sponsors reduce control arms and accelerate development without changing trial endpoints.
-
NewsProgramming immunity from within: in-body generation of CAR T cells
Researchers have developed a new method to generate CAR T cells directly inside the body using targeted lipid nanoparticles that deliver mRNA to T cells - offering a safer, faster and more accessible alternative to traditional cell therapies for cancer and autoimmune diseases.
-
ArticleInside AACR: DARPins take aim at hard-to-treat tumours
Amelie Croset of Molecular Partners breaks down the DARPin developments featured at AACR 2025 – from targeted radiopharmaceuticals to precision-engineered immune cell engagers.
-
NewsWhy PARP inhibitors fail: key role of the CST complex in BRCA1-deficient cancers
Researchers from UT Health San Antonio have identified the CST protein complex as a key driver of resistance to PARP inhibitors in BRCA1-deficient cancers – which could lead to more personalised treatments for breast, ovarian and prostate cancer patients.